Hereditary renal cancer;Cáncer de riñón hereditario

Actas Urologicas Espanolas

Volumn 33, Issue 2, 2009, Pages 127-133

  Sanz Ortega, Julián ^a,c   Olivier, Carlos ^b   Pérez Segura, Pedro ^c   Romo, Isabel Galante ^b   Mansó, Luis San José ^b   Saez, Mamen ^a  

^a Servicio de Anatomía Patólogica   (Spain)

^b Urologia   (Chile)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Germline mutations; HLRCC; Leiomyomas; Renal cancer; Von Hippel Lindau

Indexed keywords

CYST; GENETICS; HAIR FOLLICLE; HUMAN; KIDNEY TUMOR; LUNG DISEASE; REVIEW; SKIN TUMOR; SYNDROME; VON HIPPEL LINDAU DISEASE;

CYSTS; HAIR FOLLICLE; HUMANS; KIDNEY NEOPLASMS; LUNG DISEASES; SKIN NEOPLASMS; SYNDROME; VON HIPPEL-LINDAU DISEASE;

EID: 66149172365     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(09)74111-7     Document Type: Review

References (45)

1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
2. Linehan WM, Zbar B, Klausner DR. Renal carcinoma. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B (eds) The Metabolic and Molecular Bases of Inherited Disease (OMMBID), McGraw-Hill, New York, Chap 41,2002
3. Molino D, Sepe J, Anastasio P, De Santo NG. The history of von Hippel-Lindau disease. J Nephrol 19 Suppl. 2006; 10: S119-23.
4. Glasker S. Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Fam Cancer. 2005;4:37-42.
5. Kreusel KM. Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications. Fam Cancer. 2005;4: 43-47.
6. Webster AR, Maher ER, Moore AT. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol. 1999;117:371-378.
7. Iliopoulos O. von Hippel-Lindau disease: genetic and clinical observations. Front Horm Res. 2001;28:131-166.
8. Giannini C, Scheithauer BW, Davis DH. Peripheral nerve hemangioblastoma. Mod Pathol. 1998;11:999-1004.
9. Choo D, Shotland L, Mastroianni M, Linehan WM, Oldfield EH. Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg. 2004;100: 480-487.
10. Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, Linehan WM, Glenn GM, Choyke PL. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology. 2002;225: 751-758.
11. Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT, Junien C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 1998;26:256-258.
12. Rasmussen A, Nava-Salazar S, Yescas P, Alonso E,Revuelta R,Ortiz I,Canizales-Quinteros S,Tusié-Luna MT, Lopez-Lopez M: Von Hippel-Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastoma.J Neurosurg 2006 Mar;104(3):389-394.
13. American Society of Clinical Oncology. ASCO policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003; 21: 2397-2406.
14. Sgambati MT, Stolle C, Zbar B, Linehan WM, Glenn GM. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet. 2000;66:84-91.
15. Zbar B, Kishida Tet al. Germline mutations in the (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8:348-357.
16. Stebbins CE, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999;284:455-461.
17. Maher ER, Greenstein RM. The von Hippel-Lindau germline mutation V84L manifests as early-onset bilateral pheochromo-cytoma. Am J Med Genet A. 2006;140:685-690.
18. Grubb RL III, Choyke PL, Linehan WM, Walther MM. Management of von Hippel-Lindau-associated kidney cancer. Nat Clin Pract Urol. 2005;2:248-255.
19. Kovacs G: Molecular cytogenetics of renal cell tumour. Adv Cancer Res. 1993;62:89-124.
20. Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculo-mas with trichodiscomas and acrochordons. Arch Dermatol. 1997;113:1674-1677.
21. Birt-Hogg-Dube gene (FLCN) causes dominantly inherited spontaneous pneumothorax. Am J Hum Genet. 2005;76:522-527.
22. American Society of Clinical Oncology. ASCO policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
23. Linehan WM, Zbar B, Walther MM. The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU Int 95 Suppl. 2005;2:2-7.
24. Da Silva NF, Gentle D, Maher ER. Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J Med Genet. 2003;40:820-4.
25. Toro JR, Glenn G, Duray P, Linehan M, Turner ML. Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol. 1999; 135:1195-1202.
26. Nickerson ML, Toro JR, Merino M, Linehan WM, Zbar B, Schmidt LS. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2:157-164.
27. Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres CA, Merino MJ, Zbar B, Linehan WM. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst. 2005; 97:931-939.
28. Schmidt LS, Toro JR, Merino MJ, Turner ML, Zbar B, Linehan WM. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet. 2005;76:1023-1033.
29. Pavlovich CP, Grubb RL III, Linehan WM. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol. 2005; 173:1482-1486.
30. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001; 98:3387-3392.
31. Alam NA, Tomlinson IP. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol. 2005; 141: 199-206.
32. Alam NA, Rowan AJ, Wortham NC, Pollard PJ, Tomlinson IP. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyoma-tosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet. 2003; 12: 1241-1252.
33. Kiuru M, Lehtonen R, Arola J, Salovaara R, Jarvinen H, Aittomaki K, Sjoberg J, Visakorpi T, Knuutila S, Aaltonen LA. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 2002; 62: 4554-4557.
34. Toro JR, Nickerson ML, Linehan WM, Schmidt LS, Zbar B. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003; 73: 95-106.
35. Grubb RL 3rd, Franks ME, Toro J; et al: Hereditary leiomyo-matosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cance. 2007 Jun;177(6): 2074-2079.
36. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125-127.
37. Al-Saleem T, Wessner LL, Henske EP. Malignant tumors of the kidney, brain and soft tissues in children and young adults with the TSC. Cancer 1998; 83:2208-2216.
38. Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66: 792-796.
39. European Chromosome 16 Tuberous Sclerosis Consortium. Identification of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305-1315.
40. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol. 2004;19:643-649.
41. Au KS, Williams AT, Gambello MJ, Northrup H. Molecular genetic basis of tuberous sclerosis complex: from bench to bedside. J Child Neurol. 2004; 19: 699-709.
42. Oesterling JE, Fishman EK, Goldman SM, Marshall FF. The management of renal angiomyolipoma. J Urol. 1986; 135: 1121-1124.
43. Pea M, Bonetti F, Martignoni G, Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. Am J Surg Pathol. 1998;22:180-187.
44. Jones AC, Shyamsundar MM, Cheadle JP. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999; 64:1305-1315.
45. Sancak O, Nellist M, Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005;13:731-741.